Leiguang Ye

951 citations
18 papers · 631 indexed · h-index 11
Topics
Cancer Immunotherapy and Biomarkers (4 papers)Cancer-related molecular mechanisms research (4 papers)Monoclonal and Polyclonal Antibodies Research (4 papers)

In The Last Decade

Leiguang Ye

17 papers receiving 627 citations

Peers

Leiguang Ye
Comparison fields: 5 of 68
  • Molecular Biology 382
  • Oncology 228
  • Immunology 199
  • Cancer Research 187
  • Pulmonary and Respiratory Medicine 94
Replace Xueqing Yao with:
Xueqing Yao China
Galina M. Kiriakova United States
Atsuko Ashida Japan
Sonia H.Y. Kung Canada
Henrique O. Duarte Portugal
Ya-Fang Chang United States
Lucas Fass United States
Jinxue Zhou China
Guo‐Liang Shen China
Svasti Haricharan United States
Leiguang Ye relative to Xueqing Yao China Xueqing Yao's profile →
Citations per field
00.5×10×17×
Xueqing Yao · 1×
Citations per year

Countries citing papers authored by Leiguang Ye

Since Specialization
Citations

This map shows the geographic impact of Leiguang Ye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leiguang Ye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leiguang Ye more than expected).

Fields of papers citing papers by Leiguang Ye

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leiguang Ye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leiguang Ye. The network helps show where Leiguang Ye may publish in the future.

Co-authorship network of co-authors of Leiguang Ye

This figure shows the co-authorship network connecting the top 25 collaborators of Leiguang Ye. A scholar is included among the top collaborators of Leiguang Ye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leiguang Ye. Leiguang Ye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
#WorkIndexed citations
1 0
2 1
3 2
4 3
5 12
6 39
7 4
8 20
9 82
10
MicroRNA-590-3p inhibits invasion and metastasis in triple-negative breast cancer by targeting Slug.
18
11 282
12 45
13 35
14 7
15 23
16 3
17 21
18 34

About Leiguang Ye

Leiguang Ye is a scholar working on Cancer Research, Biotechnology and Immunology, having authored 18 papers that have together received 631 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (4 papers), Cancer-related molecular mechanisms research (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). The work is most often cited by research in Cancer Research (187 citations), Immunology (199 citations) and Oncology (228 citations). Leiguang Ye has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Baogang Liu, Meisi Yan, Mien‐Chie Hung, Heng‐Huan Lee, Fang� Yang, Chih‐Yen Tu, Xuan Hong, Gabriel N. Hortobágyi, Shao‐Chun Wang and Chia‐Hung Chen. Their work appears in journals such as Journal of Clinical Oncology, Cancer Cell and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026